Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$0.34 USD
+0.01 (2.82%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.34 0.00 (0.21%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SEEL 0.34 +0.01(2.82%)
Will SEEL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SEEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SEEL
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
SEEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SEEL
Seelos Therapeutics Navigates Financial and Board Changes
Psychedelic drug developers could benefit from NIH funding for chronic pain
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
12 Health Care Stocks Moving In Monday's After-Market Session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday